Below are the most recent publications written about "Cell Line, Tumor" by people in Profiles.
-
Kane GI, Diaz-Infante MB, Wigglesworth K, Lusi E, Brassil M, Rozen EJ, Kady J, Mori H, Lukas J, Naylor T, Dinnell RW, Murphy KC, Alarcon CBB, Ruscetti M, Brehm M, Shohet JM, Atukorale PU. Tumor Homing Nanoparticle Immunotherapy for Acute Clearance and Mitigation of T-cell Exhaustion in Humanized High-Risk Neuroblastoma. Mol Cancer Ther. 2026 Jul 02; 25(7):1144-1156.
-
Deshpande C, Khanduja S, Rondthaler SN, Andrews LB, Forbes NS. Suppression of Salmonella Effectors with CRISPRi Controls the Immune Response to Bacterial Therapies. ACS Synth Biol. 2026 Jul 17; 15(7):2912-2924.
-
Das A, Malley R, Bailes JE, Bobustuc GC, Varma AK, Lindhorst SM, Cachia D. Effects of Galectin-3 inhibitors paired with direct current stimulation in preclinical models of aggressive meningioma. Mol Biol Rep. 2026 Jun 27; 53(1).
-
Parikh CN, DeMarco KD, Bhalerao N, Giwa HK, Kane GI, Dinnell RW, Ma B, Mori H, Brassil ML, Murphy KC, Zhao Z, Johnson C, Ramani S, Zhou L, Chibaya L, Qiao Y, Hu K, Zhu LJ, Lewis BC, Xue W, Pitarresi JR, Atukorale PU, Ruscetti M. Multiplexed cytokine and antigen mRNA administration generates durable anti-tumor immunity against pancreatic cancer. Nat Commun. 2026 Jun 19; 17(1).
-
Khanduja S, Raman V, Hall CL, Howell LM, Van Dessel N, Forbes NS. Salmonella vector creates de novo parvovirus that reduces solid tumors and forms antitumor immune memory. Cell Rep Med. 2026 Jun 16; 7(6):102839.
-
Cui W, Xiao H, Wen X, Li C, Bao S, Long Y, Yang X, Wang K, Guo Q, Huang J. CEMs-SELEX: DNAzyme-powered de novo biomarker discovery and noninvasive cancer diagnosis. Sci Adv. 2026 May 29; 12(22):eaee7184.
-
Weiss GJ, Loftus JC, Mallery DW, Tran NL. Structure-guided identification and biological evaluation of reversible EGFR C797S inhibitors. Sci Rep. 2026 May 04; 16(1).
-
Jamroze A, Liu X, Hou S, Jess Li W, Yu H, Tracz A, Jacobi J, Li Q, Nastiuk K, Chen X, Huang J, Lin K, Liu M, Cai C, Lu Y, Puzanov I, Kirk JS, Chatta G, Tang DG. Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer. Signal Transduct Target Ther. 2026 May 01; 11(1).
-
Porto SA, Birdsall GA, Harper NW, Honeywell ME, Leighow SM, Naylor TE, Ward KM, Wesley MK, Pritchard JR, Lee MJ. Genome-wide profiling identifies the genetic dependencies of cell death following EGFR inhibition. J Biol Chem. 2026 May; 302(5):111414.
-
Cui W, Xiao H, Wen X, Li C, Bao S, Zeng J, Li Y, Qiao Y, Wang K, Wang H, Huang J, Guo Q. Identifying a cancer therapeutic target: Cell-SELEX identifies a membrane protein for aptamer-mediated growth suppression. Proc Natl Acad Sci U S A. 2026 Mar 31; 123(13):e2514681123.